Therapeutic Horizons for Dry AMD

Related

• 

  Baseline Characteristics in the Phase 2 GOLDEN Study of IONIS-FB-LRx, an Investigational Antisense Oligonucleotide Designed to Treat AMD-Associated Geographic Atrophy

  Glenn J. Jaffe, MD

  Annual Meeting Talks

  2022

• 

  Ten-Year Follow-up Data From the AREDS2 Study

  Emily Y. Chew, MD

  Updates from the Field

  2021

• 

  Geographic Atrophy in the Canadian Treat and Extend Trial With Ranibizumab in nAMD Patients: CANTREAT Study 24-Month Results

  Peter J. Kertes, MD, FRCS(C)

  Annual Meeting Talks

  2019